1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Inhaled Drug Delivery to 2022 : Drugs, Devices, Markets and Forecasts

The upper airway diseases Asthma and COPD remain significant health challenges for both patients and clinicians. Inhalers that combine two drugs indicated for treating upper airway diseases in one inhaler are gaining interest due to the complementary therapeutic effects of certain classes of drugs when taken together. Systemic delivery continues to represent an area of significant opportunity. Products and product candidates in this category include inhaled drugs for the treatment of such diverse conditions as pulmonary arterial hypertension, neurological disorders, hereditary diseases and pain management.

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application

What You Will Learn

• Which therapeutic drugs are delivered via aerosol inhalers, dry powder inhalation and
nebulizers for upper respiratory conditions? For systemic delivery?
• What are the inhalable drugs currently in development, their formulation and device strategies, and targeted indication(s) and what are market prospects?
• What are the key inhalation device technologies for commercial and development-stage devices, and what are the product technology issues and related market factors?
• What are the current market dynamics of inhaled drug targeted disease segments, and what are the growth prospects and market potential for inhaled therapeutic drugs?
• What is the current market share for inhaled drugs by product? By supplier? What will it be in seven years?
• Who are the Inhaled drug product market participants, their products, market strategies, product development activity, and partners?

Table Of Contents

Inhaled Drug Delivery to 2022 : Drugs, Devices, Markets and Forecasts
Executive Summary

The Orally Inhaled Drug Delivery Market
Therapeutic Targets
Upper Respiratory
Systemic Inhaled Delivery
Demand Drivers
Risk Factors

Competing Technologies
Dry Powder Inhalers
Metered Dose Inhalers
Nebulizers

Inhalation Technology and Product Development Factors
Formulation Factors
Drug Formulations
Formulation Technologies
Excipients and Release Profiles

Inhalation Device Design Factors
Dry Powder Inhalers
Metered Dose Inhalers
Nebulizers

Inhaler Performance Factors
Bioavailability
Dose Reproducibility
Active Compound Stability
Testing and Packaging

Inhalation Devices - Product and Device Assessments
Dry Powder inhalers
Metered Dose Inhalers
Nebulizers

Inhaled Drugs - Therapeutic Segment Analysis and Forecasts
Upper Respiratory Indications
Asthma
COPD
Systemic Drug Delivery
Bioterror
Cardiovascular Medicine
Pulmonary Hypertension
Diabetes
Hereditary Diseases
Cystic Fibrosis
Immunology
Infectious Diseases
Osteoporosis
Neurology
Oncology

Market Factors
Regulatory Issues
Patient Compliance
Healthcare Economics
Connected Devices

Market Sector Company Profiles

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects Summary Type 2 diabetes ...

Bovine Respiratory Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Bovine Respiratory Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

Global Bovine Respiratory Disease Treatment Market: Overview Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.